The company will present data at the oncology meeting showing the drug’s significant survival benefit in patients with advanced renal cancer and recurrent, persistent and metastatic cervical cancer.

Merck & Co. Inc. and Eisai Co. Ltd. said on Friday they were discontinuing a late-stage study of Keytruda plus Lenvima for the treatment of adults with unresectable or metastatic melanoma, as the trial did not show improvement in overall survival.

Keytruda, could be on its way to snagging another indication as a first-line therapy for endometrial cancer after the company announced positive Phase III results Friday.